Investigational drug · Phase 2
MEN1703
Also called: SEL24, Dapolsertib hydrochloride
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Non-Hodgkin Lymphoma, B-cell.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "MEN1703"
First trial start
2024
Dec 5, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MEN1703", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Hodgkin Lymphoma, B-cell
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "MEN1703" as an intervention, largest first.
- MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)Pivotal-lookingRecruiting
Ryvu Therapeutics SAIndustry
NCT06534437 · 178 participants (planned) · Start Dec 5, 2024 · Primary completion Dec 2026
Drug: MEN1703; Glofitamab · For: Non-Hodgkin Lymphoma, B-cell
Sites: Le Mans, France; Lille, France; Limoges, France · 35 sites in all
Menarini GroupIndustry
NCT03008187 · 73 participants · Start Mar 10, 2017 · Primary completion Apr 13, 2023
Drug: MEN1703 · For: Acute Myeloid Leukemia
Sites: Atlanta, Georgia; Cleveland, Ohio; Portland, Oregon · 15 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Dual FLT3/PIM inhibitor dapolsertib in acute myeloid leukemia: results from the phase 1/2 DIAMOND-01 trial.
Martinelli G, Solomon SR, Mukherjee S, et al. · Blood Neoplasia 2026
- In silico approaches unveil the mechanism of action of Eclipta prostrata against acute myeloid leukemia.
Islam KMT, Islam MM, Habib JB, et al. · Sci Rep 2025
- DBY-Tobacco: a dual-branch model for non-tobacco related materials detection based on hyperspectral feature fusion.
Shen C, Qi Y, Yun L, et al. · Front Plant Sci 2025
- The Dual PIM/FLT3 Inhibitor MEN1703 Combines Synergistically With Gilteritinib in FLT3-ITD-Mutant Acute Myeloid Leukaemia.
Zicari S, Merlino G, Paoli A, et al. · J Cell Mol Med 2024
- Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.
Szydowski M, Garbicz F, Jaboska E, et al. · Cancer Res 2021
- FLT3 inhibitors in acute myeloid leukemia.
Wu M, Li C, Zhu X · J Hematol Oncol 2018
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.